LGND

Ligand Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality7/10
  • Growth 6/10
  • Value 1/10
Ligand Pharmaceuticals sales and earnings growth
LGND Growth
Good
  • Revenue Y/Y 46.04%
  • EPS Y/Y 209.72%
  • FCF Y/Y 139.92%
Ligand Pharmaceuticals gross and profit margin trends
LGND Profitability
Great
  • Gross margin 95.30%
  • EPS margin 55.90%
  • ROIC 5Y 10.88%
Ligand Pharmaceuticals net debt vs free cash flow
LGND Risk
Great
  • Debt / Equity 0.5
  • Debt / FCF 2.8
  • Interest coverage 34.0

Ligand Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks